(Q45222989)

English

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study

scientific article published in July 1989

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

Everett E Vokes

3

object named as

E Vokes

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

M A Runge-Morris

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M S Kies

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

R Blough

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

L Weidner

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

R Knop

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

K Rowland

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

publication date

1 July 1989

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

2-3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

269-273

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of homoharringtonine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical investigation of homoharringtonine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine--perspectives on an active new natural product

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine as a new antileukemic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacology of homoharringtonine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of homoharringtonine administered as a 5-day continuous infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2793384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00170872

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45222989&oldid=2207155802"